Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity

Abstract

Advanced prostate cancer initially responds to hormonal treatment, but ultimately becomes resistant and requires more potent therapies. One mechanism of resistance observed in around 10–20% of these patients is lineage plasticity, which manifests in a partial or complete small cell or neuroendocrine prostate cancer (NEPC) phenotype. Here, we investigate the role of the mammalian SWI/SNF (mSWI/SNF) chromatin remodeling complex in NEPC. Using large patient datasets, patient-derived organoids and cancer cell lines, we identify mSWI/SNF subunits that are deregulated in NEPC and demonstrate that SMARCA4 (BRG1) overexpression is associated with aggressive disease. We also show that SWI/SNF complexes interact with different lineage-specific factors in NEPC compared to prostate adenocarcinoma. These data point to a role for mSWI/SNF complexes in therapy-related lineage plasticity, which may also be relevant for other solid tumors.

References 102

1. 1.

   Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394-424.

   Not in our library10.3322/caac.21492

2. 2.

   Rawla P. Epidemiology of prostate cancer. World J. Oncol. 2019;10:63-89.

   Not in our library10.14740/wjon1191

3. 3.

   Robinson D, et al. Integrative clinical genomics of advanced prostate. Cancer Cell. 2015;162:454.

   Not in our library10.1016/j.cell.2015.06.053

4. 4.

   Beltran H, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 2016;22:298-305.

   Not in our library10.1038/nm.4045

5. 5.

   Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl Acad. Sci. USA 116, 11428–11436 (2019).

   Not in our library10.1073/pnas.1902651116

6. 6.

   Epstein JI, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am. J. Surg. Pathol. 2014;38:756-767.

   Not in our library10.1097/pas.0000000000000208

7. 7.

   Rickman DS, Beltran H, Demichelis F, Rubin MA. Biology and evolution of poorly differentiated neuroendocrine tumors. Nat. Med. 2017;23:1-10.

   Not in our library10.1038/nm.4341

8. 8.

   Aggarwal R, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 2018;36:2492-2503.

   Not in our library10.1200/jco.2017.77.6880

9. 9.

   Bluemn EG, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32:474-489.

   Not in our library10.1016/j.ccell.2017.09.003

10. 10.

    Metzger AL, et al. Patterns of care and outcomes in small cell carcinoma of the prostate: a national cancer database analysis. Prostate. 2019;79:1457-1461.

    Not in our library10.1002/pros.23864

11. 11.

    Ku SY, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355:78-83.

    Not in our library10.1126/science.aah4199

12. 12.

    Mu P, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017;355:84-88.

    Not in our library10.1126/science.aah4307

13. 13.

    Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat. Rev. Urol. 2018;15:271-286.

    Not in our library10.1038/nrurol.2018.22

14. 14.

    Kadoch C, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat. Genet. 2013;45:592-601.

    Not in our library10.1038/ng.2628

15. 15.
    The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers · 2013

    No notice
16. 16.

    Kadoch C, Crabtree GR. Mammalian SWI/SNF chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics. Sci. Adv. 2015;1:e1500447.

    Not in our library10.1126/sciadv.1500447

17. 17.

    Hargreaves DC, Crabtree GR. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res. 2011;21:396-420.

    Not in our library10.1038/cr.2011.32

18. 18.

    Ho L, et al. An embryonic stem cell chromatin remodeling complex, esBAF, is an essential component of the core pluripotency transcriptional network. Proc. Natl Acad. Sci. USA. 2009;106:5187-5191.

    Not in our library10.1073/pnas.0812888106

19. 19.

    Ho L, et al. esBAF facilitates pluripotency by conditioning the genome for LIF/STAT3 signalling and by regulating polycomb function. Nat. Cell Biol. 2011;13:903-913.

    Not in our library10.1038/ncb2285

20. 20.

    Yoo AS, Staahl BT, Chen L, Crabtree GR. MicroRNA-mediated switching of chromatin-remodelling complexes in neural development. Nature. 2009;460:642-646.

    Not in our library10.1038/nature08139

21. 21.

    Wu JI, et al. Regulation of dendritic development by neuron-specific chromatin remodeling complexes. Neuron. 2007;56:94-108.

    Not in our library10.1016/j.neuron.2007.08.021

22. 22.

    Lessard J, et al. An essential switch in subunit composition of a chromatin remodeling complex during neural development. Neuron. 2007;55:201-215.

    Not in our library10.1016/j.neuron.2007.06.019

23. 23.

    Versteege I, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998;394:203-206.

    Not in our library10.1038/28212

24. 24.

    Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell. 2013;153:71-85.

    Not in our library10.1016/j.cell.2013.02.036

25. 25.

    Witkowski L, et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat. Genet. 2014;46:438-443.

    Not in our library10.1038/ng.2931

26. 26.

    Le Loarer F, et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat. Genet. 2015;47:1200-1205.

    Not in our library10.1038/ng.3399

27. 27.

    Biegel JA, Busse TM, Weissman BE. SWI/SNF chromatin remodeling complexes and cancer. Am. J. Med. Genet. C Semin. Med. Genet. 2014;166C:350-366.

    Not in our library10.1002/ajmg.c.31410

28. 28.

    Hoffman GR, et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc. Natl Acad. Sci. USA. 2014;111:3128-3133.

    Not in our library10.1073/pnas.1316793111

29. 29.
    Patient derived organoids to model rare prostate cancer phenotypes · 2018

    No notice
30. 30.

    Spahn M, et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int. J. Cancer. 2010;127:394-403.

    Not in our library10.1002/ijc.24715

31. 31.

    Prensner JR, et al. The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. Neoplasia. 2014;16:900-908.

    Not in our library10.1016/j.neo.2014.09.001

32. 32.

    Coppola V, et al. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition. Oncogene. 2013;32:1843-1853.

    Not in our library10.1038/onc.2012.194

33. 33.

    Ding Y, et al. Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. J. Clin. Invest. 2019;129:759-773.

    Not in our library10.1172/jci123557

34. 34.

    Muthuswami, R. et al. BRG1 is a prognostic indicator and a potential therapeutic target for prostate cancer. J. Cell Physiol. 234, 15194–15205 (2019).

    Not in our library10.1002/jcp.28161

35. 35.

    Hieronymus H, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006;10:321-330.

    Not in our library10.1016/j.ccr.2006.09.005

36. 36.

    Epstein, J. I. et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur. Urol. 69, 428–435 (2015).

    Not in our library10.1016/j.eururo.2015.06.046

37. 37.

    Cancer Genome Atlas Research, N. The molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011-1025.

    Not in our library10.1016/j.cell.2015.10.025

38. 38.

    Spratt DE, et al. Individual patient-level meta-analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease. J. Clin. Oncol. 2017;35:1991-1998.

    Not in our library10.1200/jco.2016.70.2811

39. 39.

    Ross AE, et al. Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men. Eur. Urol. 2016;69:157-165.

    Not in our library10.1016/j.eururo.2015.05.042

40. 40.

    Chen CD, et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004;10:33-39.

    Not in our library10.1038/nm972

Cited by papers we hold 3

• Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies · 2023
  No notice
• Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance · 2022
  Corrected
• Loss and revival of androgen receptor signaling in advanced prostate cancer · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.